In­dus­try calls for changes in two REMS guid­ances

In­dus­try groups rep­re­sent­ing the phar­ma­ceu­ti­cal, biotech­nol­o­gy and gener­ic drug in­dus­tries are call­ing for changes to two re­cent FDA draft guid­ances on REMS.

The draft guid­ances, re­leased for com­ment in Jan­u­ary, de­tail a frame­work for com­pa­nies to de­vel­op an as­sess­ment plan for their REMS pro­grams and pro­vide rec­om­men­da­tions for sur­vey­ing pa­tient and health care provider knowl­edge of REMS in­for­ma­tion.

While PhRMA says it com­mends the FDA for pro­vid­ing rec­om­men­da­tions for de­vel­op­ing REMS as­sess­ments, the group ar­gues that the guid­ance should be prospec­tive and not ap­ply to ex­ist­ing REMS that al­ready have as­sess­ments in place to min­i­mize dis­rup­tion to those pro­grams.

PhRMA says it is con­cerned that new met­rics for as­sess­ing a REMS in­tro­duced in the draft guid­ance may pose chal­lenges to spon­sors with ex­ist­ing REMS. “Such changes may sig­nif­i­cant­ly mod­i­fy the REMS pro­gram and in­crease stake­hold­er bur­den through changes to da­ta col­lec­tion re­quire­ments,” PhRMA writes.

In­stead, PhRMA asks the FDA to weigh the util­i­ty of new met­rics against how ef­fi­cient­ly they can mea­sure the ef­fec­tive­ness of the REMS.

PhRMA al­so asks the FDA for ad­di­tion­al de­tails on how met­rics on pa­tient ac­cess and bur­den to the health­care sys­tem should be in­cor­po­rat­ed in­to as­sess­ment plans. “PhRMA be­lieves that if a pre-spec­i­fied thresh­old is not met, there should be an op­por­tu­ni­ty to re­vise and im­prove the REMS goals,” PhRMA writes.

Sim­i­lar­ly, BIO calls for the FDA to clar­i­fy how the guid­ance will ap­ply to ex­ist­ing and well-es­tab­lished REMS and en­cour­ages the FDA to ex­empt ex­ist­ing REMS from eval­u­at­ing pa­tient ac­cess and bur­den on the health­care sys­tem.

BIO points out that there are dif­fer­ent chal­lenges to as­sess­ing a REMS re­quired as part of a prod­uct’s ap­proval and one re­quired af­ter ap­proval due to a post-mar­ket safe­ty is­sue. “In the case of REMS that are re­quired as part of an ini­tial ap­proval, there is no com­para­tor group of pa­tients who had ac­cess to the prod­uct with­out REMS. With­out that com­para­tor group, it is very dif­fi­cult to mea­sure the ef­fect of the REMS pro­gram on pa­tient ac­cess,” BIO writes.

Rep­re­sent­ing the gener­ic drug in­dus­try, AAM rais­es con­cerns about how the guid­ance will ap­ply to shared REMS sys­tems. “The rec­om­men­da­tions in the guid­ance are eas­i­er to im­ple­ment in a brand REMS con­text and will be much more dif­fi­cult to em­ploy for sin­gle, shared sys­tem REMS or sep­a­rate shared REMS that have mul­ti­ple AN­DA par­tic­i­pants,” AAM writes.

In its com­ments on the sur­vey method­olo­gies guid­ance, PhRMA re­quests that the FDA ex­pand the guid­ance to in­clude rec­om­men­da­tions for sur­vey­ing pa­tient and health­care prac­ti­tion­er at­ti­tudes in ad­di­tion to sur­vey­ing their knowl­edge.

The draft guid­ance spec­i­fies that pa­tients should ei­ther be cur­rent­ly tak­ing the drug or have tak­en it with­in a “rea­son­able time,” which PhRMA says should be flex­i­ble de­pend­ing on the char­ac­ter­is­tics of the drug and its dos­ing sched­ule.

The draft guid­ance al­so says that sur­vey par­tic­i­pants should not have pre­vi­ous­ly par­tic­i­pat­ed in a REMS sur­vey for the same prod­uct. “PhM­RA be­lieves this will be chal­leng­ing for spon­sors and oth­er stake­hold­ers … where the drug has been on the mar­ket for a long time, or for a rare dis­ease prod­uct used in a lim­it­ed pa­tient pop­u­la­tion and pre­scribed by a small­er num­ber of spe­cial­ized pre­scribers,” PhRMA writes.

Ad­di­tion­al­ly, PhRMA asks for more de­tails from the FDA on the util­i­ty of open-end­ed ques­tions in the sur­veys. While the guid­ance rec­om­mends sur­veys in­clude a va­ri­ety of ques­tion types, PhRMA says it be­lieves the util­i­ty of re­spons­es to open-end­ed ques­tions in this con­text would be lim­it­ed.


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Lessons for biotech and phar­ma from a doc­tor who chased his own cure

After being struck by a rare disease as a healthy third year medical student, David Fajgenbaum began an arduous journey chasing his own cure. Amidst the hustle of this year’s JP Morgan conference, the digital trials platform Medable partnered with Endpoints Studio to share Dr. Fajgenbaum’s story with the drug development industry.

What follows is an edited transcript of the conversation between Medable CEO Dr. Michelle Longmire and Dr. Fajgenbaum, and it is full of lessons for biotech executives charged with bringing the next generation of medicines to patients.

Christos Kyratsous (via LinkedIn)

He built a MERS treat­ment in 6 months and then the best Ebo­la drug. Now Chris­tos Kyrat­sous turns his sights on Covid-19

TARRYTOWN, NY — In 2015, as the Ebola epidemic raged through swaths of West Africa, Kristen Pascal’s roommates sat her down on their couch and staged an intervention.

“Are you sure this is what you want to be doing with your life?” she recalls them asking her.

Pascal, a research associate for Regeneron, had been coming home at 2 am and leaving at 6 am. At one point, she didn’t see her roommate for a week. For months, that was life in Christos Kyratsous’ lab as the pair led a company-wide race to develop the first drug that could effectively treat Ebola before the outbreak ended. For Pascal, that was worth it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,400+ biopharma pros reading Endpoints daily — and it's free.

Left to right, top to bottom: Carl Gordon, Adam Stone, Peter Moglia, David Schenkein, Robert Nelsen, Carol Gallagher; Srinivas Akkaraju, Ray Debbane, Jim Flynn, Peter Kolchinsky, Thilo Schroeder, Brad Bolzon

UP­DAT­ED: The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

The VC crowd took a step back last year, but nevertheless maintained a furious pace of new investments in therapeutic tech platforms and biotech startups. And the top 100 players completely dominated the megabillions game.

Just looking at the number of deals done by each of the top 100, OrbiMed came in at the top, with 20, followed by Alexandria (18), Perceptive (16) and the ubiquitous RA Capital at 16. It’s impossible to say exactly how much they invested in total — those numbers are only rarely provided — but it is clear from the numbers assembled by Chris Dokomajilar at DealForma who’s most likely to be found sitting at the table during the go-go days of biotech investing.

Dokomajilar tracked $14.06 billion in biotech venture investing last year, a dip from the frenzied pace of $16.02 billion in 2018 and more than $10 billion higher than he recorded for 2010, as the economy was recovering from a profound economic crisis.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Rahul Ballal, Imara

As sick­le cell pa­tients find new op­tions, NEA-found­ed Imara pitch­es mid-stage al­ter­na­tive for $86M IPO

November 2019 proved to be a fruitful month for patients with blood disorders known as hemoglobinopathies. Within days, the FDA ushered two drugs for sickle cell disease and another for beta thalassemia to the market — livening up a barren field.

Imara, a relatively young plower, is riding on that enthusiasm as it shoots for an $86.25 million IPO.

Imara emerged from New Enterprise Associates’ orphan drug accelerator Cydan in 2016 as a single-product company. $77.3 million in private financing later IMR-687 remains the sole asset in its pipeline; the difference is the drug is now in Phase II for sickle cell disease, with topline data slated for later this year and two other mid-stage beta thalassemia studies lined up.

UP­DAT­ED: RA joins glob­al syn­di­cate to back a $98M round for CAN­bridge

A Beijing-based rare disease and oncology player has raised $98 million to help fund the expansion of its pipeline as well as a commercial portfolio.

CANbridge put out word Tuesday that the global private equity player General Atlantic joined forces with Chinese CRO Wuxi AppTec to lead the Series D, with both ready to chip in an extra $10 million each under the right conditions. The syndicate includes RA Capital Management, Hudson Bay Capital Management, YuanMing Prudence Fund and Tigermed.

Carol Robinson, Professor Dame Carol Robinson Research Group

UP­DAT­ED: Drug dis­cov­ery in HD: Ox­ford spin­of­f's mass spec­trom­e­try ap­proach scores fresh fund­ing

The technology used to detect explosives at airports — mass spectrometry — is being piloted as an engine for drug discovery.

Mass spectrometry is a tool designed to measure with profound accuracy the mass of a single molecule. Typically, mass spectrometers can be used to identify unknown compounds, to quantify known compounds, and to determine the structure and chemical properties of molecules.

Lars Fruergaard Jørgensen, chief executive officer of Novo Nordisk A/S, (via Getty Images)

The list of the 11 block­busters-to-be in line for a 2020 launch high­light agony and ec­sta­sy of drug R&D

For all the talk about unmet medical need and patients first and so on, the key criteria investors watch for any new drug in the pipelines is peak sales projection. Are you going to hit the blockbuster mark, at $1 billion-plus, or are you going to be an also-ran in the sales department?

Of course, analysts’ peak sales projections by themselves are of limited value in many cases. When the PCSK9 drugs started arriving 5 years ago, Repatha was billed as a $2.5 billion peak earner. They’re nowhere near that, with new competition threatening current levels. And if Biogen’s controversial Alzheimer’s drug aducanumab (submission planned but not on the list) is approved, per chance, will payers cover it?

Maybe not. And then those $10 billion in peak sales assumptions would go straight down the drain.

But, analysts are analysts, and peak sales projections have to be factored in when assessing the top experimental drugs up for a launch in the year ahead.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Chi­na ap­proves flu drug be­ing tout­ed as a po­ten­tial coro­n­avirus treat­ment amid a rush of clin­i­cal stud­ies

One of the three drugs that China’s Ministry of Science and Technology has tapped as potential COVID-19 treatments to watch has notched its first Chinese OK — for the flu.

While there’s no proof yet that fapilavir, or favipiravir, is the cure that patients and physicians are yearning for, it stands out for a unique constellation of qualities. It’s been commercially available in Japan for several years (unlike Gilead’s experimental remdesivir) yet it’s new to China (unlike the malaria drug chloroquine phosphate). Perhaps more importantly, a domestic biotech — Zhejiang Hisun Pharma — owns the rights to manufacture and market the drug, preempting any concerns about patents.

FDA goes on high alert as coro­n­avirus rais­es threat to drug man­u­fac­tur­ing and clin­i­cal tri­als grind to a halt

The FDA isn’t quite sure just what the coronavirus outbreak in China will mean for the US pharma industry, but it has the potential to trigger a host of troublesome issues around the supply chain the country is directly plugged into.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,400+ biopharma pros reading Endpoints daily — and it's free.